Pancreatic cancer remains one of oncology's most intractable challenges, with five-year survival rates stubbornly below 12%. A new mechanistic insight could shift how researchers think about why these tumors resist treatment: the answer may partly lie in how lactate — the metabolic byproduct of aerobic glycolysis — chemically modifies proteins rather than simply acidifying the tumor microenvironment.
Using integrative genomic analysis across TCGA and GEO datasets combined with experimental cell and xenograft models, investigators identified a five-gene lactylation-associated signature — comprising LRP3, TTLL6, TSGA13, PRKCG, and SDK2 — capable of stratifying pancreatic adenocarcinoma (PAAD) patients into distinct survival risk groups. High-risk tumors characterized by this signature exhibited an immunosuppressive microenvironment marked by reduced immune cell infiltration, Th2-skewed immune remodeling, and elevated checkpoint activation. The most mechanistically illuminating finding centered on PRKCG (Protein Kinase C gamma), which was significantly downregulated in PAAD tissue and correlated with advanced disease stage and poorer outcomes. When PRKCG was overexpressed experimentally, tumor proliferation, migration, and invasion were suppressed and apoptosis increased. Critically, lactate-induced lactylation at specific PRKCG sites impaired its ability to activate the p53 tumor suppressor pathway — not by reducing PRKCG protein levels, but by functionally silencing it post-translationally.
This lactate-PRKCG-p53 axis represents a conceptually meaningful advance. Lactylation — the direct addition of lactyl groups to lysine residues on proteins — was only described as a histone modification in 2019, and its non-histone targets in cancer biology are still being mapped. This study extends that frontier into a therapeutically relevant signaling cascade. Key limitations include the reliance on public datasets for the prognostic model, mouse xenograft rather than immunocompetent models for in vivo validation, and the absence of patient-derived organoid data. Whether pharmacological restoration of PRKCG activity or lactylation site-blocking strategies can be translated clinically remains an open question, but the mechanistic specificity here elevates this beyond routine biomarker discovery.